Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : French court finds Bayer's Monsanto liable for farmer's sickness

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2019 | 01:00pm EDT
French cereal farmer Paul Francois, head of the Phyto-Victims association, attends a news conference, after the verdict in his appeals trial against U.S. Monsanto firm, in Paris

PARIS/LYON (Reuters) - A French court has ruled that Monsanto was liable for the sickness of a farmer who inhaled one of its weedkillers, in another legal setback for the Bayer-owned business over health claims.

In the latest stage of a decade-long legal tussle, the appeals court in Lyon on Thursday found in favour of farmer Paul Francois' claim that Monsanto's Lasso weedkiller had made him sick and that the product's labelling had been inadequate.

Francois, 55, says he suffered neurological problems, including memory loss, fainting and headaches, after accidentally inhaling Lasso in 2004 while working on his farm.

"Mr Francois justifiably concludes that the product, due to its inadequate labelling that did not respect applicable regulations, did not offer the level of safety he could legitimately expect," the court said in its ruling.

The latest verdict, however, did not determine compensation for the farmer, which will now be considered by another court in Lyon.

Francois is seeking about 1 million euros (862,034.70 pounds) in damages.

Bayer, which acquired Monsanto in a $63 billion deal last year, said it was considering its legal options, including an appeal before France's highest court.

The German chemicals group added that crop-protection products "do not pose a risk for human health if they are used according to the terms of use set out in their regulatory approval".

Mr Francois had won rulings against Monsanto in 2012 and 2015 before France's top court overturned the decisions and ordered the new hearing in Lyon.

"We are all happy to have won but it came at a heavy price," Francois told reporters in Paris.

"It's a big sigh of relief. It's been 12 years of fighting, 12 years during which I had to put my whole life on hold."

Lasso was banned in France in 2007 after the product had been withdrawn in some other countries.

It used a different active substance to glyphosate, the chemical contained in Monsanto's best-selling weedkiller Roundup and the target of lawsuits in the United States over alleged cancer links.

The company has been found liable in two trials in California brought by cancer sufferers who have been awarded tens of millions of dollars in damages. Bayer is appealing against those rulings.

The legal troubles surrounding glyphosate have contributed to Bayer losing about 30 billion euros in market value since last August. The group's chief executive on Thursday said it was "massively affected" by the litigation.

After the announcement of the decision, Bayer's shares extended a fall to trade about 1.5 percent down before recovering some of the losses.

(Reporting by Catherine Lagrange in Lyon, Simon Carraud and Gus Trompiz in Paris; Additional reporting by Sybille de La Hamaide; Editing by Jane Merriman and David Goodman)

By Simon Carraud and Catherine Lagrange

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 2.90% 61.35 Delayed Quote.-1.59%
VALUE8 0.71% 5.7 Delayed Quote.19.41%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
02:05aBAYER AKTIENGESELLSCHAFT : Preliminary announcement of the publication of financ..
EQ
07/22BAYER : Iberogast Drug Is Safe
DJ
07/22BAYER : sells Dr. Scholl's foot care business to Boston firm
AQ
07/22BAYER : Sells Dr. Scholl's Brand to Yellow Wood Partners for $585 Million
DJ
07/22BAYER COULD BENEFIT FROM HOME ADVANT : experts
RE
07/22BAYER : Drug Iberogast Under Investigation -Handelsblatt
DJ
07/19BAYER : Syngenta profits hit by U.S./China trade wars, bad weather
RE
07/19BAYER : welcomes judge's call for reduced damages in $2 billion glyphosate case
RE
07/19BAYER : Correction to Bayer Verdict Article
DJ
07/19Does renewables pioneer Germany risk running out of power?
RE
More news
Financials (EUR)
Sales 2019 46 326 M
EBIT 2019 8 877 M
Net income 2019 3 589 M
Debt 2019 37 542 M
Yield 2019 4,77%
P/E ratio 2019 17,1x
P/E ratio 2020 12,5x
EV / Sales2019 2,02x
EV / Sales2020 1,90x
Capitalization 55 860 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 77,90  €
Last Close Price 59,90  €
Spread / Highest target 105%
Spread / Average Target 30,0%
Spread / Lowest Target -35,3%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-1.59%62 672
JOHNSON & JOHNSON0.98%341 546
PFIZER-2.02%237 728
ROCHE HOLDING LTD.8.73%230 511
ROCHE HOLDING10.69%230 511
NOVARTIS24.78%216 127